Literature DB >> 33429429

Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer.

Barbara Burtness1,2, Joseph Contessa2,3.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33429429      PMCID: PMC8168139          DOI: 10.1093/jnci/djaa187

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  18 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Authors:  T Y Seiwert; C C Foster; E A Blair; T G Karrison; N Agrawal; J M Melotek; L Portugal; R J Brisson; A Dekker; S Kochanny; Z Gooi; M W Lingen; V M Villaflor; D T Ginat; D J Haraf; E E Vokes
Journal:  Ann Oncol       Date:  2019-10-01       Impact factor: 32.976

3.  Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.

Authors:  John V Hegde; Narek Shaverdian; Megan E Daly; Carol Felix; Deborah L Wong; Michael H Rosove; Jordan H Garst; Pin-Chieh Wang; Darlene Veruttipong; Shyam Rao; Ruben C Fragoso; Jonathan W Riess; Michael L Steinberg; Allen M Chen
Journal:  Cancer       Date:  2017-10-17       Impact factor: 6.860

4.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

Authors:  Shanthi Marur; Shuli Li; Anthony J Cmelak; Maura L Gillison; Weiqiang J Zhao; Robert L Ferris; William H Westra; Jill Gilbert; Julie E Bauman; Lynne I Wagner; David R Trevarthen; Jahagirdar Balkrishna; Barbara A Murphy; Nishant Agrawal; A Dimitrios Colevas; Christine H Chung; Barbara Burtness
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

5.  Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.

Authors:  Allen M Chen; Carol Felix; Pin-Chieh Wang; Sophia Hsu; Vincent Basehart; Jordan Garst; Phillip Beron; Deborah Wong; Michael H Rosove; Shyam Rao; Heather Melanson; Edward Kim; Daphne Palmer; Lihong Qi; Karen Kelly; Michael L Steinberg; Patrick A Kupelian; Megan E Daly
Journal:  Lancet Oncol       Date:  2017-04-20       Impact factor: 41.316

6.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

7.  Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.

Authors:  Nils H Nicolay; Nicole Wiedenmann; Michael Mix; Wolfgang A Weber; Martin Werner; Anca L Grosu; Gian Kayser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-07       Impact factor: 9.236

8.  Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.

Authors:  Nadeem Riaz; Eric Sherman; Xin Pei; Heiko Schöder; Milan Grkovski; Ramesh Paudyal; Nora Katabi; Pier Selenica; Takafumi N Yamaguchi; Daniel Ma; Simon K Lee; Rachna Shah; Rahul Kumar; Fengshen Kuo; Abhirami Ratnakumar; Nathan Aleynick; David Brown; Zhigang Zhang; Vaios Hatzoglou; Lydia Y Liu; Adriana Salcedo; Chiaojung J Tsai; Sean McBride; Luc G T Morris; Jay Boyle; Bhuvanesh Singh; Daniel S Higginson; Rama R Damerla; Arnaud da Cruz Paula; Katharine Price; Eric J Moore; Joaquin J Garcia; Robert Foote; Alan Ho; Richard J Wong; Timothy A Chan; Simon N Powell; Paul C Boutros; John L Humm; Amita Shukla-Dave; David Pfister; Jorge S Reis-Filho; Nancy Lee
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

9.  TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.

Authors:  Michael Hajek; Andrew Sewell; Susan Kaech; Barbara Burtness; Wendell G Yarbrough; Natalia Issaeva
Journal:  Cancer       Date:  2017-03-13       Impact factor: 6.860

10.  Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomics.

Authors:  Stefan P Haider; Kariem Sharaf; Tal Zeevi; Philipp Baumeister; Christoph Reichel; Reza Forghani; Benjamin H Kann; Alexandra Petukhova; Benjamin L Judson; Manju L Prasad; Chi Liu; Barbara Burtness; Amit Mahajan; Seyedmehdi Payabvash
Journal:  Transl Oncol       Date:  2020-10-16       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.